Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Presentation (March 2012)
20 slides from Novo Nordisk A/s Class B's investor presentation, Mar 12, 2012
Slide 1: Investor Presentation, Sydbank, Svendborg Teater
Investor Presentation Sydbank, Svendborg Teater 12 March 2012
Slide 2: Forward-looking statements
Investor Presentation Sydbank 12 March 2012 Slide no 2 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2011 and Form 20-F, both expected to be filed with the S
Slide 3: Content
Investor Presentation Sydbank 12 March 2012 Slide no 3 Content Highlights and key events Sales update R&D update Financials and outlook
Slide 4: Highlights - full year 2011
Investor Presentation Sydbank 12 March 2012 Slide no 4 Highlights - full year 2011 Sales development • Sales increased by 11% in local currencies driven by Victoza® and modern insulins • Victoza® sales reached DKK 5,991 million (growth of 159% in DKK) • Healthcare reforms impacted sales growth negat
Slide 5: Victoza and modern insulins continue to drive growth
Investor Presentation Sydbank 12 March 2012 Slide no 5 Victoza® and modern insulins continue to drive growth – full year 2011 Sales as reported Growth analysis Other Local currencies Growth Share of Norditropin® +13% growth +5% 4% Modern insulins 11% 41% 8% Human insulins (8%) (14%) NovoSeven® +4% V
Slide 6: North America continues to drive sales growth
Investor Presentation Sydbank 12 March 2012 Slide no 6 North America continues to drive sales growth – full year 2011 Sales as reported Growth analysis Region China Local currencies Growth Share of +11% growth Japan & Korea North America 18% 61% +10% 8% Europe 2% 6% 9% North America International Op
Slide 7: Novo Nordisk strategic injectable therapies exhibit steady sales growth
Investor Presentation Sydbank 12 March 2012 Slide no 7 Novo Nordisk strategic injectable therapies exhibit steady sales growth Sales as reported Key growth drivers DKK billion • Steady growth in global diabetes prevalence • Clear strategic focus on expanding and Total: achieving leadership in CAGR 2
Slide 8: Novo Nordisk continues to expand leadership position within diabetes care
Investor Presentation Sydbank 12 March 2012 Slide no 8 Novo Nordisk continues to expand leadership position within diabetes care Global diabetes care market Global diabetes care by treatment class value market share DKK billion Novo Nordisk Lilly BMS GLP-1 Insulin OAD 30% Takeda Merck Novartis Total
Slide 9: Global insulin volume continues to grow as the diabetes pandemic expands
Investor Presentation Sydbank 12 March 2012 Slide no 9 Global insulin volume continues to grow as the diabetes pandemic expands Number of people with diabetes Regional insulin volume growth continues to grow North America China Million people North America Europe China Europe International Operation
Slide 10: Victoza reached blockbuster status in 2011
Investor Presentation Sydbank 12 March 2012 Slide no 10 Victoza® reached blockbuster status in 2011 Reported Victoza® sales Victoza® sales split per region DKK North America Europe billion Int. Operations Japan & Korea 5% 6% 27% 62% Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY 2011 sales of DKK 6.0 billion 2009 20
Slide 11: Victoza continues to drive the growth of the GLP-1 class in the US
Investor Presentation Sydbank 12 March 2012 Slide no 11 Victoza® continues to drive the growth of the GLP-1 class in the US Expansion of the GLP-1 market Key observations for the US market GLP-1 TRx scripts (thousands) GLP-1 % of diabetes market value (right axis) • Close to 70% of new patients come
Slide 12: In key European markets Victoza has expanded the GLP-1 class to nearly 10%
Investor Presentation Sydbank 12 March 2012 Slide no 12 In key European markets Victoza® has expanded the GLP-1 class to nearly 10% of the diabetes market Development in key European GLP-1 markets following Victoza® launch Germany UK France Market value*: DKK 10 billion Market value*: DKK 5 billion
Slide 13: Degludec and DegludecPlus regulatory update
Investor Presentation Sydbank 12 March 2012 Slide no 13 Degludec and DegludecPlus regulatory update • New drug applications (NDA) submitted to FDA on 29 September 2011 USA • FDA review ongoing, PDUFA action date set for 29 July 2012 • NDA submitted to EMA on 26 September 2011 EU • EMA review ongoing
Slide 14: Research and Development update
Investor Presentation Sydbank 12 March 2012 Slide no 14 Research and Development update Diabetes care and obesity • Degludec and DegludecPlus regulatory process progressing according to plan in Europe, US, Japan1 Switzerland and Canada • In two 52+52 weeks extension trials2 in people with type 1 and
Slide 15: Significant growth opportunities fuelled by strong R&D pipeline
Investor Presentation Sydbank 12 March 2012 Slide no 15 Significant growth opportunities fuelled by strong R&D pipeline Diabetes care Degludec/ NN1218 – ultra NN1953 – oral DegludecPlus fast acting insulin insulin NN9926 – oral IdegLira Liraglutide depot GLP-1 Liraglutide for NN9924 – oral Semagluti
Slide 16: Financial results – full year 2011
Investor Presentation Sydbank 12 March 2012 Slide no 16 Financial results – full year 2011 DKK million 2011 2010 Change Sales 66,346 60,776 9% Gross profit 53,757 49,096 9% Gross margin 81.0% 80.8% Sales and distribution costs 19,004 18,195 4% Percent of sales 28.6% 29.9% Research and development co
Slide 17: Cash generated is returned to shareholders in form of dividends and share buybacks
Investor Presentation Sydbank 12 March 2012 Slide no 17 Cash generated is returned to shareholders in form of dividends and share buybacks Dividend and payout ratio Share repurchases programmes DKK Payout DKK Share repurchase programme 2007-2010 Dividend paid Payout ratio billion ratio billion Expan
Slide 18: Financial outlook 2012
Investor Presentation Sydbank 12 March 2012 Slide no 18 Financial outlook 2012 Expectations 2 February 2012 Sales growth - local currencies 7-11% Around 4 percentage points higher than Sales growth - reported growth in local currencies Operating profit growth - local Around 10% currencies Operating
Slide 19: Closing remarks
Investor Presentation Sydbank 12 March 2012 Slide no 19 Closing remarks Solid market performance Promising pipeline • +10% annual diabetes care market growth • The only company with two new generation driven by diabetes prevalence1 insulins submitted for approval • 24% market share in diabetes care
Slide 20: Investor information
Investor Presentation Sydbank 12 March 2012 Slide no 20 Investor information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York Stock E